Advertisement
Research ArticleNEUROPHARMACOLOGY

Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2C Receptors

John F. Cryan and Irwin Lucki
Journal of Pharmacology and Experimental Therapeutics December 2000, 295 (3) 1120-1126;

Abstract

The role of the 5-HT2C receptor in mediating active behaviors in the modified rat forced swim test was examined. Three novel selective 5-HT2C receptor agonists, WAY 161503 (0.1–3.0 mg/kg), RO 60-0175 (2–20 mg/kg), and RO 60-0332 (20 mg/kg), all decreased immobility and increased swimming, a pattern of behavior similar to that which occurs with the selective serotonin reuptake inhibitor fluoxetine (5–20 mg/kg). However, the prototypical but nonselective 5-HT2C receptor agonistm-chlorophenylpiperazine (1–10 mg/kg) increased immobility scores in the forced swim test. The selective 5-HT2C receptor antagonist SB 206533 was inactive when given alone (1–20 mg/kg). However, SB 206533 (20 mg/kg) blocked the antidepressant-like effects of both WAY 161503 (1 mg/kg) and fluoxetine (20 mg/kg). The atypical antidepressant (noradrenergic α2and 5-HT2C receptor antagonist) mianserin reduced immobility and increased climbing at 30 mg/kg. At a behaviorally subactive dose (10 mg/kg), mianserin abolished the effects of WAY 161503 (1 mg/kg) on both swimming and immobility scores. Mianserin blocked the effects of fluoxetine (20 mg/kg) on swimming only; mianserin plus fluoxetine reduced immobility and induced a switch to climbing behavior, suggesting activation of noradrenergic transmission. These data exemplify the benefits of using the modified rat forced swim test, which was sensitive to serotonergic compounds and distinguished behavioral changes associated with serotonergic and noradrenergic effects. Taken together, the results strongly implicate a role for 5-HT2C receptors in the behavioral effects of antidepressant drugs.

The indoleamine serotonin (5-hydroxytryptamine, 5-HT) plays a major role in the pathogenesis and treatment of various psychiatric disorders including depression (Maes and Meltzer, 1995; Lucki, 1998). Selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed class of drugs for the treatment of clinical depression. SSRIs are believed to exert their antidepressant ability by blocking the reuptake of serotonin at synaptic terminals, resulting in an elevation of extracellular 5-HT concentrations in limbic regions of the brain that can act on various critical postsynaptic 5-HT receptors (Goodnick and Goldstein, 1998). At least 14 different subtypes of 5-HT receptors have been identified (Barnes and Sharp, 1999), and it is still unclear which of them are most relevant to the pathogenesis of depression and the mechanism of action of antidepressants (Cryan and Leonard, 2000). Whereas clinical and animal studies have strongly implicated 5-HT1A, 5-HT1B, and 5-HT2A receptors as playing a critical role in the antidepressant response (Lucki et al., 1994; Barnes and Sharp, 1999; Cryan and Leonard, 2000), there has been less emphasis on other 5-HT receptor subtypes. This has been attributable, in part, to the unavailability of selective ligands.

The 5-HT2C receptor (formerly 5-HT1C) (Baxter et al., 1995) is a postsynaptically located, seven-transmembrane spanning receptor present in highest concentrations in the choroid plexus, but significant densities are also found in the subthalamic nucleus, hypothalamus, hippocampus, and amygdala (Mengod et al., 1990). The 5-HT2C receptor is believed to have an integral function in the control of many physiological and behavioral responses, including feeding, anxiety, temperature regulation, locomotion, sexual behavior, and the occurrence of seizures (Lucki et al., 1989; Kennett, 1993; Baxter et al., 1995). The first indication that this receptor may be relevant to antidepressant action occurred when it was realized that the atypical antidepressant mianserin has a high affinity for it (Pazos et al., 1984). Subsequently, a number of antidepressants, especially tricyclics, were shown to have high to moderate affinity for the 5-HT2C receptor (Jenck et al., 1993, 1994).Berendson and Broekkamp (1987, 1994) and others (Leander, 1987;Lucki et al., 1988) have shown that SSRIs may exert some of their behavioral effects in vivo by 5-HT2C receptor activation. Indeed, a number of common behavioral effects are produced by both 5-HT2C receptor agonists and SSRIs, including inhibition of escape from aversive periaqueductal gray stimulation, decreased defensive burying, induction of penile erections, hypophagia, and inhibition of muricide (Broekkamp and Berendson, 1992)

There have been relatively few studies investigating the role of 5-HT2C receptors in animal behavior tests sensitive to antidepressants. The forced swim test (FST) as originally described by Porsolt et al. (1977) is the most widely used pharmacological model for assessing antidepressant activity (Weiss and Kilts, 1998). Rats develop immobility when they are placed in a cylinder of water without the opportunity for escape. The immobile behavior is thought to reflect either a failure to persist in escape-directed behavior after persistent stress or the development of passive behavior that disengages the animal from active forms of coping with stressful stimuli (Lucki, 1997). A broad spectrum of antidepressant drugs selectively prevents the development of behavioral immobility in the FST (Borsini and Meli, 1988). However, a recent modification of the traditional FST demonstrated that specific behavioral components of active behaviors in the FST distinguished neurochemically distinct antidepressant drugs (Lucki, 1997). The modified FST differentiated swimming behavior, which was sensitive to SSRIs and 5-HT receptor agonists, and climbing behavior, which was sensitive to tricyclic antidepressants and drugs with selective effects on catecholamine transmission (Detke et al., 1995; Lucki, 1997). The distinctive active behaviors produced by pharmacologically selective antidepressants persisted with chronic treatment (Detke et al., 1997), and they were superimposable on combinations of serotonergic and catacholaminergic compounds (Reneric and Lucki, 1998). The increased swimming behavior produced by fluoxetine has been shown to be prevented by pretreatment with the tryptophan hydroxylase inhibitor parachlorophenylalanine but not the increased climbing produced by the norepinephrine reuptake inhibitor desipramine (Page et al., 1999). Although the modified rat FST is sensitive to the effects of serotonergic antidepressants, it is unclear which serotonergic receptors are responsible for the mediation of these antidepressant-sensitive behaviors. Therefore, the following series of studies were aimed at investigating the role of the 5-HT2C receptor in mediating selective antidepressant-like effects in the modified rat FST.

Materials and Methods

Animals.

A total of 458 male Sprague-Dawley rats (Charles River, Wilmington, MA) weighing from 175 to 200 g on arrival were used in these studies. The animals were housed in pairs in polycarbonate cages and maintained on a 12-h light:dark cycle (lights on at 7:00 AM) in a temperature-controlled (22°C) colony. The animals had free access to food and water. Animals were handled daily for at least 5 days before initiation of behavioral testing. Behavioral studies were carried out in the afternoon (12:00–6:00 PM) during the months of July through November. All experimental procedures were carried out in accordance with protocols approved by the University of Pennsylvania Institutional Animal Care and Use Committee.

Rat Forced Swim Test.

The modified rat forced swim test was conducted essentially as described by Detke et al. (1995). Briefly, rats were placed individually for 15 min in Pyrex cylinders (21 × 46 cm; Fisher Scientific, Pittsburgh, PA) that were filled with water to a depth of 30 cm. They were removed after 15 min, dried, and placed in their home cage. Twenty-four hours after their first exposure, the animals were replaced in the swim apparatus for 5 min, and the session was recorded using a video camera placed above the cylinder for subsequent analysis. Animals were randomly assigned to groups receiving various drug treatments or to a control group (0.9% saline). Injections were administered s.c. three times (1, 5, and 23.5 h) before the test session. The rater of the behavioral patterns was blind to the experimental conditions being scored. A time sampling technique was used whereby the predominant behavior in each 5-s period of the 300-s test was recorded. Climbing behavior consisted of upward-directed movements of the forepaws along the side of the swim chamber. Swimming behavior was defined as movement (usually horizontal) throughout the swim chamber, which also included crossing into another quadrant. Immobility was assigned when no additional activity was observed other than that required to keep the rat's head above the water.

The first study examined in a dose-response manner the effects of fluoxetine on active behaviors in the modified rat FST. The effects of three recently developed selective 5-HT2Creceptor agonists, WAY 161503, RO 60-0175, and RO 60-0332, were then investigated in the FST. These compounds are distinguished from conventional agonists, such as m-CPP and (±)-1-(2,5-dimethoxy-4-iodophenyl) 2-aminopropane, by their greater selectivity for 5-HT2C over 5-HT2A receptors. WAY 161503 (Wyeth-Ayerst, Princeton, NJ) is a novel selective and potent 5-HT2C receptor agonist (Rosenzweig-Lipson et al., 2000). In binding studies using [125I](±)-1-(2,5-dimethoxy-4-iodophenyl) 2-aminopropane with human 5-HT2C and 5-HT2A receptors, WAY 161503 shows an approximate 3-fold selectivity for 5-HT2C over 5-HT2A receptors with an affinity of 3 nM. In functional studies using human receptors, WAY 161503 shows an approximate 2000-fold selectivity for 5-HT2C over 5-HT2A receptors with an EC50 value of approximately 8 nM at the 5-HT2C receptor in an agonist-stimulated inositol monophosphate formation assay (Rosenzweig-Lipson et al., 2000). RO 60-0175 and RO 60-0332 have been the most widely studied of the recently developed generation of selective 5-HT2Creceptor agonists (Moreau et al., 1996; Martin et al., 1998). Both compounds have at least greater than 25-fold affinity for the 5-HT2C receptor over the 5-HT2A receptor (RO 60-0175, 5-HT2C pKi = 9.0 versus 5-HT2A pKi = 7.5; RO 60-0332, 5-HT2CpKi = 8.5 versus 5-HT2A pKi = 7.0) (Martin et al., 1998). For comparison, we also investigated the effects of the prototypical, but nonselective, 5-HT2Creceptor agonist m-CPP on active behaviors in the FST.

The next set of studies focused on the effects of the potent selective 5-HT2C receptor antagonist SB 206533 (Kennett et al., 1996) alone and in combination with fluoxetine and with WAY 161503 on active behaviors in the test. SB 206533 has a greater than 100-fold affinity for 5-HT2C receptors over 5-HT2A receptors (pKi= 7.9 versus 5.8) (Kennett et al., 1996), but it also has substantial affinity for the 5-HT2B receptor (pKi = 8.9).

To complement these studies, we examined the effects of the antidepressant mianserin, which is a nonselective 5-HT2C receptor antagonist, given alone and in combination with fluoxetine or WAY 161503, on active behaviors in the test. Mianserin has similar affinity for 5-HT2Aand 5-HT2C receptors but has a lower affinity for the 5-HT2B receptor (pKi = 8.0, 8.1, and 7.3, respectively) (Baxter et al., 1995).

Drugs.

All drugs were freshly made before use and were injected s.c. in a volume of 2 ml/kg. Fluoxetine (Eli Lilly and Co., Indianapolis, IN), mianserin (Organon, Oss, The Netherlands), and WAY 161503 (Wyeth-Ayerst) were dissolved in deionized H2O and sonicated mildly. m-CPP (Research Biochemicals, Natick, MA) dissolved readily in distilled H2O. The selective 5-HT2Creceptor agonists RO 60-0175 (F. Hoffmann-La Roche, Basel, Switzerland), RO 60-0332 (F. Hoffmann-La Roche), and the 5-HT2C receptor antagonist SB 206533 (Wyeth-Ayerst) were crushed using a pestle and mortar and moistened with 1 to 2 drops of Tween 80 (Sigma, St. Louis, MO). The resultant paste was suspended and brought up to volume with deionized H2O. We have shown previously that the addition of small amounts of Tween 80, as used in these studies, does not have an impact on behavioral effects in the rat FST (Detke et al., 1995). For combination experiments, both drugs were made up in the same solution to eliminate any confounding stress effects of multiple injections. All drug doses were calculated as the base weight, except RO 60-0175 and RO 60-0332, which were calculated without correction.

Statistical Analysis.

ANOVA was carried out in all studies. Any overall statistical differences were analyzed further using Fisher's post hoc tests.

Results

As shown in Fig. 1, fluoxetine dose dependently decreased immobility [F(3,52) = 5.21; P < .05] while inducing a corresponding increase in swimming behavior [F(3,52) = 8.70; P < .001] without having any effect on climbing behavior [F(3,52) = 0.27; P = .85]. Similar effects were seen after the administration of the selective 5-HT2C receptor agonists (Fig.2). WAY 161503, RO 60-0175, and RO 60-0332 decreased immobility scores [F(5,54) = 2.69,P < .05; F(3,36) = 4.45,P = .009; and F(3,36) = 3.49,P < .05, respectively]. This was accompanied by an increase in swimming behavior for each agonist [F(5,54) = 3.76,P < .01; F(3,36) = 5.31,P < .01; and F(3,36) = 3.04,P < .05, respectively]. None of the three 5-HT2C receptor agonists altered climbing behavior [F(5,54) = 0.57, P = .57;F(3,36) = 0.35, P = .79; andF(3,36) = 0.78, P = .51, respectively].

Figure 1
Figure 1

The effects of the SSRI fluoxetine on active behaviors in a modified rat forced swim test. Fluoxetine (5 mg/kg,n = 14; 10 mg/kg, n = 14; 20 mg/kg,n = 13) decreased immobility and increased swimming behavior compared with that in saline-treated animals (n = 15). All bars represent mean values with vertical lines indicating 1 S.E.M. Asterisks indicate groups that differed significantly from saline-treated animals: *P < .05.

Figure 2
Figure 2

The effects of novel 5-HT2Creceptor agonists on active behaviors in a modified rat forced swim test. A, WAY 161503 (0.1 mg/kg, n = 9; 0.3 mg/kg,n = 10; 0.6 mg/kg, n = 11; 1.0 mg/kgn = 10; 3.0 mg/kg, n = 10) decreased immobility and increased swimming behavior compared with that in saline-treated animals (n = 10). B, RO 60-0175 decreased immobility and increased swimming behavior compared with that in saline-treated animals (all groups, n = 10). C, RO 60-0332 decreased immobility and increased swimming behavior compared with that in saline-treated animals (all groups, n = 10). All bars represent mean values with vertical lines indicating 1 S.E.M. Asterisks indicate groups that differed significantly from saline-treated animals: *P < .05.

The effects of the nonselective 5-HT2C receptor agonist m-CPP are shown in Fig.3. m-CPP administration caused a dose-dependent increase in immobility [F(3,36) = 3.50, P < .05] and a corresponding decrease in climbing behavior [F(3,36) = 7.57, P< .001] without having any effect on swimming behavior [F(3,36) = 0.07, P = .98].

Figure 3
Figure 3

The effects of the nonselective 5-HT2C receptor agonist m-CPP on active behaviors in a modified rat forced swim test. m-CPP (1 mg/kg, n = 10; 3 mg/kg, n = 11; 10 mg/kg, n = 10) increased immobility and decreased climbing behavior compared with that in saline-treated animals (n = 9). Asterisks indicate groups that differed significantly from saline-treated animals: *P < .05. (Note that the y-axis scale is different from that in the other graphs.)

The 5-HT2C receptor antagonist SB 2060533 did not alter immobility [F(4,42) = 0.87, P = .49], swimming [F(4,42) = 0.94, P = .45], or climbing [F(4,42) = 0.46, P= .76] behaviors in the rat forced swim test at all doses tested when given alone (Fig. 4A). When SB 206533 was administered in combination with either WAY 161503 (1 mg/kg) or fluoxetine (20 mg/kg), there was a significant overall effect of drug treatment on immobility [F(5,73) = 7.85,P < .001], on swimming [F(5,73) = 14.66, P < .001], but not on climbing [F(5,73) = 0.33, P = .89]. Post hoc analysis demonstrated that both WAY 161503 and fluoxetine decreased immobility and increased swimming behavior. These effects were completely antagonized by combined treatment with the 5-HT2C receptor antagonist SB 206533, which had no effect on any behavioral parameter when administered on its own (Fig. 4B).

Figure 4
Figure 4

The effects of the 5-HT2Creceptor antagonist SB 206533 alone or in combination with WAY 161503 or fluoxetine on active behaviors in a modified rat forced swim test. A, SB 206533 (1 mg/kg, n = 10; 3 mg/kg,n = 10; 10 mg/kg, n = 9; 20 mg/kg,n = 9) failed to alter any of the rat behaviors in the forced swim test compared with behaviors in saline-treated animals (n = 9). B, WAY 161503 alone (1 mg/kg,n = 13) and fluoxetine alone (20 mg/kg,n = 13) both decreased immobility and increased swimming behavior compared with that in saline-treated animals (n = 14). SB 206533 alone (20 mg/kg, n= 13) or in combination with WAY 161503 (1 mg/kg, n = 13) or fluoxetine (20 mg/kg, n = 13) failed to alter any behavioral parameter. All bars represent mean values with vertical lines indicating 1 S.E.M. Asterisks indicate groups that differed significantly from saline-treated animals: *P < .05.

As shown in Fig. 5A, the 5-HT2C receptor antagonist/atypical antidepressant mianserin altered immobility [F(3,38) = 3.93, P < .05] and climbing behavior [F(3,38) = 7.71, P < .001] without having any effect on swimming behavior [F(3,38) = 0.58, P = .63]. Post hoc analysis revealed that only the highest dose of mianserin (30 mg/kg) reduced immobility and increased climbing behavior, whereas the other doses did not affect any behavioral parameters. The effects of mianserin, at a behaviorally inactive dose (10 mg/kg), given in combination with either WAY 161503 (1 mg/kg) or fluoxetine (20 mg/kg), were then examined and the results are shown in Fig. 5B. ANOVA demonstrated that there was a significant alteration of immobility [F(5,49) = 4.75,P = .001], swimming[F(5,49) = 18.94,P < .001], and climbing behavior [F(5,49) = 2.85, P < .05]. Post hoc analysis confirmed that both fluoxetine and WAY 161503 reduced immobility and increased swimming behavior without altering climbing scores. Mianserin significantly abolished the effects of WAY 161503 when given in combination. In addition, mianserin counteracted the fluoxetine-induced increase in swimming behavior. However, mianserin caused an increase in climbing behavior when combined with fluoxetine and therefore did not block fluoxetine's effect on immobility. Mianserin at the dose used had no effect of its own on any of the behavioral parameters.

Figure 5
Figure 5

The effects of the nonselective 5-HT2C receptor antagonist mianserin, given alone or in combination with WAY 161503 or fluoxetine, on active behaviors in a modified rat forced swim test. A, mianserin at doses of 3 mg/kg (n = 9) or 10 mg/kg (n = 9) failed to alter active behaviors. At the higher dose of 30 mg/kg (n = 10) mianserin caused a decrease in immobility with a corresponding increase in climbing behavior compared with that in saline-treated animals (n = 10). B, WAY 161503 alone (1 mg/kg, n = 8) and fluoxetine alone (20 mg/kg,n = 9) both decreased immobility and increased swimming behavior compared with that in saline-treated animals (n = 9). Mianserin alone (10 mg/kg, n = 9) and in combination with WAY 161503 (1 mg/kg, n = 10) failed to alter any behavioral parameter. However, mianserin given in combination with fluoxetine (20 mg/kg, n = 10) produced a significant decrease in immobility and increase in climbing behavior. All bars represent mean values with vertical lines indicating 1 S.E.M. Asterisks indicate groups that differed significantly from the group of saline-treated animals: * P < .05.

Discussion

The precise specification of the neural mechanisms underlying the effects of antidepressant drugs can identify novel candidates involved in the pathophysiology of depression and possible new targets for therapeutic intervention. In this study, we provided direct evidence for a role of the 5-HT2C receptor in mediating the antidepressant-like behavioral effects of both the novel 5-HT2C receptor agonist WAY 161503 and those of the SSRI and established antidepressant drug fluoxetine. Three selective 5-HT2C receptor agonists, WAY 161503, RO 60-0175, and RO 60-0332, were demonstrated to have antidepressant potential in the modified rat FST paradigm. Although fluoxetine and the three novel 5-HT2C receptor agonists produced qualitatively similar responses in the modified rat FST, the effects of fluoxetine could be attributable either to its direct action at the 5-HT2C receptor or to an indirect consequence of 5-HT transporter blockade. The latter seems more likely because prior depletion of 5-HT prevented the antidepressant behavioral response of fluoxetine (Page et al., 1999). This initial demonstration of common effects of all three novel 5-HT2C receptor agonists with the SSRI fluoxetine in the rat FST paradigm suggested that compounds with similar actions may have clinical antidepressant ability. Both RO 60-0175 and RO 60-0332 have been shown previously to be active in other animal models of depression (Moreau et al., 1996;Martin et al., 1998), but the specificity of their behavioral effects for the 5-HT2C receptor was not investigated using antagonism studies. The fact that SB 206533 antagonized the antidepressant-like behavioral effects of both WAY 161503 and fluoxetine suggests that these effects were mediated by the activation of 5-HT2C receptors. Although SB 206533 is also a 5-HT2B receptor antagonist, the functional relevance of this effect is not known. Previous behavioral studies have shown that SB 206533 is effective at blocking 5-HT2C receptor-mediated behaviors induced bym-CPP (Kennett et al. 1996) and more selective 5-HT2C receptor agonists such as RO 60-0175 (Sukoff and Rosenzweig-Lipson, 1999).

There have been a number of views of the role of the 5-HT2C receptor in antidepressant action. Some studies have shown that chronic treatment with SSRIs and monoamine oxidase inhibitors attenuated certain putative 5-HT2C receptor-mediated behavioral responses in rats (Lucki et al., 1989; Maj and Moryl, 1992; Kennett et al., 1994) and blunted neuroendocrine responses to 5-HT2Creceptor agonists (Quested et al., 1997; but see Li et al., 1993), suggesting that these antidepressant drug treatments are capable of producing functional desensitization of these receptors. In contrast,Berendson and Broekkamp (1987, 1994) demonstrated that fluoxetine in vivo may produce behavioral effects by activating 5-HT2C receptors. They and others using different behavioral tests (Borsini et al., 1991; Cesana et al., 1993; Moreau et al., 1996) suggested that the activation of 5-HT2C receptors may be responsible in part for the antidepressant properties of fluoxetine and other antidepressants. The common effects of multiple 5-HT2C receptor agonists, the ineffectiveness of the 5-HT2Creceptor antagonist SB 206533, and the ability to block behavioral responses of fluoxetine and WAY 161503 by pretreatment with 5-HT2C receptor antagonists support the idea that the activation of 5-HT2C receptors was responsible for antidepressant-like behavioral responses in the rat FST.

Mianserin is an effective 5-HT2C receptor antagonist but is also a potent antagonist of 5-HT2A and of α1- and α2-adrenergic receptors (Fludder and Leonard, 1979). It also has a lower affinity for the 5-HT2B receptor than does SB 206533 (Baxter et al., 1995). Before more selective antagonists were available that discriminate between 5-HT2A and 5-HT2C receptors, mianserin was used extensively to probe 5-HT2C receptor function in both behavioral and neurochemical studies (e.g., Lucki et al., 1989). In this study, mianserin was shown to produce antidepressant-like effects in the rat FST. The behavioral pattern, as manifested by an increase in climbing behavior, suggests that its response was more likely associated with effects on noradrenergic transmission (i.e., α2-adrenergic receptor blockade) as opposed to effects on the 5-HT2C receptor. Previous studies have shown that selective catecholaminergic compounds increase climbing behavior, whereas serotonergic antidepressants selectively increase swimming behavior (Detke et al., 1995; Reneric and Lucki, 1998; Page et al., 1999). The more selective 5-HT2C receptor antagonist SB 206533 produced no effects in the FST, further supporting that the effects of mianserin are catecholamine in origin.

A behaviorally subactive dose of mianserin also blocked the increases in swimming behavior produced by WAY 161503 and fluoxetine. Interestingly, when mianserin was added to fluoxetine, it caused a switch in the behavior associated with fluoxetine from swimming to climbing. Switching between behavioral components of the modified FST has been reported previously with the combined treatment of the noradrenergic reuptake inhibitor desipramine with fluoxetine or with the nonselective reuptake inhibitor venlafaxine (Reneric and Lucki, 1998), and the expression of both behavioral components may predict more effective antidepressant drug treatments (Lucki, 1997). Because the affinity of fluoxetine for the 5-HT transporter is only an order of magnitude greater than that for the norepinephrine transporter (Goodnick and Goldstein, 1998), fluoxetine treatment can impact noradrenergic neurotransmission (Li et al., 1996; Gobert et al., 1997). With the combined administration of mianserin and fluoxetine, at a dose of mianserin that is subactive in our behavioral paradigm but that increases discharge of the noradrenergic nucleus locus ceruleus (Curtis and Valentino, 1991), a synergistic effect on climbing behavior was seen. It is tempting to speculate that the addition of α2 receptor blockade by mianserin to the inhibition of 5-HT reuptake blockade by fluoxetine might enhance effects on catecholamine and serotonergic transmission through a variety of potential mechanisms (Gobert et al., 1997). Because the pattern of behavior produced by mianserin and fluoxetine combinations manifested in an increase in climbing behavior, a response mediated by catecholamines, mianserin may have augmented any effects of fluoxetine on catecholamine transmission past the threshold where they would influence behavior. These data from the mianserin/fluoxetine combination study are but one example of the utility of specifying active behaviors in the FST because otherwise, mianserin's blockade of fluoxetine's antidepressant-like effects, i.e., swimming behavior, could not be shown. The combination of mianserin with fluoxetine may lead to augmentation of their clinical effects (Maes et al., 1999).

Most challenge studies that have examined functional responses associated with 5-HT2C receptor activation have relied on the use of m-CPP as a 5-HT2Creceptor agonist. However, the lack of effect of m-CPP in the rat FST, even though it has substantial affinity for 5-HT2C receptors, indicates that its behavioral effects may be complicated by effects at many other receptors with which it interacts (Murphy et al., 1991). The inactivity ofm-CPP in the FST could be attributable to behavioral suppression caused by its potent inhibitory effects on general locomotion (Lucki et al., 1989). Nevertheless, as with many antidepressants, RO 60-0175, RO 60-0332, and WAY 161503 at behaviorally active doses in the FST have been shown to produce similar hypomotility effects that do not obscure their antidepressant-like effects (Martin et al., 1998; S. Rosenzweig-Lipson, personal communication). Another possibility is that the effects of m-CPP on immobility may be mediated through its actions at the 5-HT1Breceptor. Previous studies have shown that activation of 5-HT1B receptors can block the anti-immobility effects of desipramine in the rat FST (Cervo et al., 1989; but seeSchlicker et al., 1992). It is of interest that the antidepressant nefazodone, which has m-CPP as one of its primary metabolites, is inactive in this test (J. F. Cryan and I. Lucki, unpublished observations). This effect may also be attributable to functional antagonism by m-CPP through its actions at the 5-HT1B receptor. It is unclear whether there are other functional responses that might be produced by newly selective 5-HT2C receptor agonists that would differ from those produced by m-CPP.

Several 5-HT receptor subtypes, alone or interdependent with the 5-HT2C receptor, are likely to play a role in the mediation of antidepressant effects. Other 5-HT receptors such as 5-HT1A, 5-HT1B, and 5-HT2A receptors have been suggested to mediate antidepressant responses and play a role in the responses produced by SSRIs (Lucki et al., 1994; Berendson, 1995). Although the 5-HT2C receptor antagonist SB 2060533 completely blocked behavioral responses to fluoxetine, the FST paradigm used was not designed to reveal a residual role for other 5-HT receptors in the effects of fluoxetine. Nevertheless, results with novel and selective 5-HT2C receptor agonists present new evidence that the 5-HT2C receptor may indeed be a novel target for the development of antidepressants and perhaps of drugs effective in other psychiatric disorders involving 5-HT (Lucki, 1998).

Acknowledgments

We thank Dr. Paul McGonigle and Dr. Sharon Rosenzweig-Lipson from Wyeth-Ayerst Pharmaceuticals, Princeton, NJ, for the gifts of WAY 161503 and SB 206533 and for helpful comments regarding some of the studies. We acknowledge Dr. Jean-Luc Moreau, F. Hoffmann-La Roche, Basel, Switzerland, for the generous gifts of RO 60-0175 and RO 60-0332. We also value the advice from Dr. Michelle Page, University of Pennsylvania, in the preparation of this manuscript.

Footnotes

  • Send reprint requests to: Dr. Irwin Lucki, Department of Psychiatry, University of Pennsylvania, 538A Clinical Research Bldg., 415 Curie Blvd., Philadelphia, PA 19104-6140. Email:lucki{at}pharm.med.upenn.edu

  • ↵1 This research was supported by U.S. Public Heath Service Grant MH 36262.

  • Abbreviations:
    5-HT
    5-hydroxytryptamine (serotonin)
    FST
    forced swim test
    SSRI
    selective serotonin reuptake inhibitor
    m-CPP
    1-(3-chlorophenyl)piperazine 1:2
    WAY 161503
    8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a-]quinoxalin-5-one
    RO 60-0175
    (S)-2-(chloro-5-fluoro-indol-1-yl)-1-methylethylamine 1:1 C4H4O4
    RO 60-0332
    (S)-2-(4,4,7-trimethyl-1,4-dihydro-indeno[1,2-b]pyrrol-1-methylethylamine 1:1 1:1 C4H4O4
    SB 206553
    (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole)
    • Received March 30, 2000.
    • Accepted August 11, 2000.

References

  1. ↵
    1. Barnes NM,
    2. Sharp T
    (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Baxter G,
    2. Kennett G,
    3. Blaney F,
    4. Blackburn T
    (1995) 5-HT2 receptor subtypes: A family reunited? Trends Pharmacol Sci 16:105–110.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Berendson HHG
    (1995) Interactions between 5-hydroxytryptamine receptor sub-types: Is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacol Ther 66:17–37.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Berendson HHG,
    2. Broekkamp CLE
    (1987) Drug-induced penile erections in rats: Indications of serotonin1B receptor mediation. Eur J Pharmacol 135:279–287.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Berendson HHG,
    2. Broekkamp CLE
    (1994) Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure. Eur J Pharmacol 253:83–89.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Borsini F,
    2. Cesana R,
    3. Vidi A,
    4. Mennini T
    (1991) Evidence that imipramine activates 5-HT1C receptor function. Eur J Pharmacol 203:359–363.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Borsini F,
    2. Meli A
    (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94:147–160.
    OpenUrlPubMed
  8. ↵
    1. Broekkamp CLE,
    2. Berendsen HHG
    (1992) The importance of 5-HT1C-receptors for antidepressant effects. Pol J Pharmacol Pharm 44 (Suppl 20) 20.
    OpenUrl
  9. ↵
    1. Cervo L,
    2. Grignaschi G,
    3. Nowakowska E,
    4. Samanin R
    (1989) 1-(3-Trifluoromethylphenyl) piperazine (TFMPP) in the ventral tegmental area reduces the effect of desipramine in the forced swimming test in rats: Possible role of serotonin receptors. Eur J Pharmacol 171:119–125.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cesana R,
    2. Ceci A,
    3. Ciprandi C,
    4. Borsini F
    (1993) Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol 45:473–475.
    OpenUrlPubMed
  11. ↵
    1. Cryan JF,
    2. Leonard BE
    (2000) 5-HT1A and beyond—The role of serotonin and its receptors in depression and the antidepressant response. Hum Psychopharmacol 15:113–135.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Curtis AL,
    2. Valentino RJ
    (1991) Acute and chronic effects of the atypical antidepressant, mianserin on brain noradrenergic neurons. Psychopharmacology 103:330–338.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Detke MJ,
    2. Johnson J,
    3. Lucki I
    (1997) Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5:107–112.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Detke MJ,
    2. Rickels M,
    3. Lucki I
    (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66–72.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Fludder JM,
    2. Leonard BE
    (1979) Chronic effects of mianserin on noradrenaline metabolism in the rat brain: Evidence for a pre-synaptic alpha-adrenolytic action in vivo. Psychopharmacology 64:329–332.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Gobert A,
    2. Rivet JM,
    3. Cistarelli L,
    4. Melon C,
    5. Millan MJ
    (1997) Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 69:2616–2619.
    OpenUrlPubMed
  17. ↵
    1. Goodnick PJ,
    2. Goldstein BJ
    (1998) Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol 12:S5–S20.
  18. ↵
    1. Jenck F,
    2. Moreau J-L,
    3. Mutel V,
    4. Martin JR
    (1994) Brain 5-HT1C receptors and antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry 18:563–574.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Jenck F,
    2. Moreau J-L,
    3. Mutel V,
    4. Martin JR,
    5. Haefely WE
    (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223–229.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Kennett GA
    (1993) 5-HT1C receptors and their therapeutic relevance. Curr Opin Invest Drugs 2:317–362.
  21. ↵
    1. Kennett GA,
    2. Lightowler S,
    3. De Biasi V,
    4. Stevens NC,
    5. Wood MD,
    6. Tulloch IF,
    7. Blackburn TP
    (1994) Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function. Neuropharmacology 33:1581–1588.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kennett GA,
    2. Wood MD,
    3. Bright F,
    4. Cilia J,
    5. Piper DC,
    6. Gager T,
    7. Thomas D,
    8. Baxter GS,
    9. Forbes IT,
    10. Ham P,
    11. Blackburn TP
    (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT 2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427–434.
    OpenUrlPubMed
  23. ↵
    1. Leander JD
    (1987) Fluoxetine suppressed palatability-induced ingestion. Psychopharmacology 91:285–287.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Li MY,
    2. Yan QS,
    3. Coffey LL,
    4. Reith ME
    (1996) Extracellular dopamine, norepinephrine, and serotonin in the nucleus accumbens of freely moving rats during intracerebral dialysis with cocaine and other monoamine uptake blockers. J Neurochem 66:559–568.
    OpenUrlPubMed
  25. ↵
    1. Li Q,
    2. Brownfield MS,
    3. Battaglia G,
    4. Cabrera TM,
    5. Levy AD,
    6. Rittenhouse PA,
    7. Van de Kar LD
    (1993) Long-term treatment with the antidepressants fluoxetine and desipramine potentiates responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI). J Pharmacol Exp Ther 266:836–844.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Lucki I
    (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523–532.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Lucki I
    (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151–162.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Lucki I,
    2. Kreider MS,
    3. Simansky KJ
    (1988) Reduction of feeding behavior by the serotonin uptake inhibitor sertraline. Psychopharmacology 96:289–295.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Lucki I,
    2. Singh A,
    3. Kreiss DS
    (1994) Behavioral studies of serotonin receptor agonists as antidepressant drugs. Neurosci Biobehav Rev 18:85–95.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Lucki I,
    2. Ward HR,
    3. Frazer A
    (1989) Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249:155–164.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Maes M,
    2. Libbrecht I,
    3. van Hunsel F,
    4. Campens D,
    5. Meltzer HY
    (1999) Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19:177–182.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Bloom FE,
    2. Kupfer DJ
    1. Maes M,
    2. Meltzer HY
    (1995) The serotonin hypothesis of major depression. in Psychopharmacology: The Fourth Generation of Progress, eds Bloom FE, Kupfer DJ (Raven Press, New York), pp 933–944.
  33. ↵
    1. Maj J,
    2. Moryl E
    (1992) Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm 88:143–156.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Martin JR,
    2. Bos M,
    3. Moreau J-L,
    4. Mutel V,
    5. Wichmann J,
    6. Andrews JS,
    7. Berendsen HHG,
    8. Broekkamp CLE,
    9. Ruigt GS,
    10. Kohler C,
    11. Delft AM
    (1998) 5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Mengod G,
    2. Nguyen H,
    3. Le H,
    4. Waeber C,
    5. Lubbert H,
    6. Palacios JM
    (1990) The distribution and cellular localization of the serotonin1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience 35:577–591.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Moreau J-L,
    2. Bos M,
    3. Jenck F,
    4. Martin JR,
    5. Mortas P,
    6. Wichmann J
    (1996) 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 6:169–175.
    OpenUrlPubMed
  37. ↵
    1. Murphy DL,
    2. Lesch KP,
    3. Aulakh CS,
    4. Pigott TA
    (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 43:527–552.
    OpenUrlPubMed
  38. ↵
    1. Page ME,
    2. Detke MJ,
    3. Dalvi A,
    4. Kirby LG,
    5. Lucki I
    (1999) Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147:162–167.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Pazos A,
    2. Hoyer D,
    3. Palacios JM
    (1984) The binding of serotonergic ligands to the porcine choroid plexus: Characterisation of a new type of serotonin recognition site. Eur J Pharmacol 106:539–542.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Porsolt RD,
    2. Le Pichon M,
    3. Jalfre M
    (1977) Depression: A new animal model sensitive to antidepressant treatments. Nature (Lond) 266:730–732.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Quested DJ,
    2. Sargent PA,
    3. Cowen PJ
    (1997) SSRI treatment decreases prolactin and hyperthermic responses to m-CPP. Psychopharmacology 133:305–308.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Reneric JP,
    2. Lucki I
    (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136:190–197.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Rosenzweig-Lipson S,
    2. Coupet J,
    3. Dunlop J,
    4. McGonigle P
    (2000) Antiobesity-like effects of the selective 5-HT2C agonist WAY 161503. FASEB J 14:A1321.
    OpenUrl
  44. ↵
    1. Schlicker E,
    2. Werner U,
    3. Hamon M,
    4. Gozlan H,
    5. Nickel B,
    6. Szelenyi I,
    7. Gothert M
    (1992) Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 105:732–738.
    OpenUrlPubMed
  45. ↵
    1. Sukoff S,
    2. Rosenzweig-Lipson S
    (1999) Comparison of the 5-HT2C antagonist properties of the 5-HT2C/2B antagonist SB 206533 and RS-102221in rats. Behav Pharmacol 10:S90.
    OpenUrl
  46. ↵
    1. Nemeroff CB,
    2. Schatzberg AF
    1. Weiss JM,
    2. Kilts CD
    (1998) Animal models of depression and schizophrenia. in Textbook of Psychopharmacology, eds Nemeroff CB, Schatzberg AF (American Psychiatric Association Press, New York), pp 88–123.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleNEUROPHARMACOLOGY

Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2C Receptors

John F. Cryan and Irwin Lucki
Journal of Pharmacology and Experimental Therapeutics December 1, 2000, 295 (3) 1120-1126;
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement